Cargando…

Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial

Treating Veterans with chronic obstructive pulmonary disease complicated by pulmonary hypertension (COPD‐PH) using phosphodiesterase type‐5 inhibitor pharmacotherapy is common, but efficacy data are lacking. To address this further, patients with COPD‐PH from five Department of Veterans Affairs hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Maron, Bradley A., Choudhary, Gaurav, Goldstein, Rebekah L., Garshick, Eric, Jankowich, Matthew, Tucker, Troo J. S., LaCerda, Kathleen A., Hattler, Brack, Dempsey, Edward C., Sadikot, Ruxana T., Shapiro, Shelley, Rounds, Sharon I., Goldstein, Ronald H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053004/
https://www.ncbi.nlm.nih.gov/pubmed/35506072
http://dx.doi.org/10.1002/pul2.12043
_version_ 1784696904560410624
author Maron, Bradley A.
Choudhary, Gaurav
Goldstein, Rebekah L.
Garshick, Eric
Jankowich, Matthew
Tucker, Troo J. S.
LaCerda, Kathleen A.
Hattler, Brack
Dempsey, Edward C.
Sadikot, Ruxana T.
Shapiro, Shelley
Rounds, Sharon I.
Goldstein, Ronald H.
author_facet Maron, Bradley A.
Choudhary, Gaurav
Goldstein, Rebekah L.
Garshick, Eric
Jankowich, Matthew
Tucker, Troo J. S.
LaCerda, Kathleen A.
Hattler, Brack
Dempsey, Edward C.
Sadikot, Ruxana T.
Shapiro, Shelley
Rounds, Sharon I.
Goldstein, Ronald H.
author_sort Maron, Bradley A.
collection PubMed
description Treating Veterans with chronic obstructive pulmonary disease complicated by pulmonary hypertension (COPD‐PH) using phosphodiesterase type‐5 inhibitor pharmacotherapy is common, but efficacy data are lacking. To address this further, patients with COPD‐PH from five Department of Veterans Affairs hospitals were randomized (1∶1) to receive placebo or oral tadalafil (40 mg/day) for 12 months. The primary endpoint was changed from baseline in 6‐min walk distance at 12 months. Secondary endpoints included change from baseline in pulmonary vascular resistance, mean pulmonary artery pressure, and symptom burden by the University of California San Diego shortness of breath questionnaire scale at 6 months. A total of 42 subjects (all male; 68 ± 7.6 years old) were randomized to placebo (N = 14) or tadalafil (N = 28). The group imbalance was related to under‐enrollment. Compared to placebo, no significant difference was observed in the tadalafil group for change from the primary endpoint or change in mean pulmonary artery pressure or pulmonary vascular resistance from baseline at 6 months. A clinically meaningful improvement was observed in the secondary endpoint of shortness of breath questionnaire score in the tadalafil versus placebo group at 6 months. There was no significant difference in major adverse events between treatment groups, and tadalafil was well tolerated overall. For Veterans with COPD‐PH enrolled in this study, once‐daily treatment with tadalafil did not improve 6‐min walk distance or cardiopulmonary hemodynamics although a decrease in shortness of breath was observed. Under‐enrollment and imbalanced randomization confound interpreting conclusions from this clinical trial and limit the generalization of our findings.
format Online
Article
Text
id pubmed-9053004
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90530042022-05-02 Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial Maron, Bradley A. Choudhary, Gaurav Goldstein, Rebekah L. Garshick, Eric Jankowich, Matthew Tucker, Troo J. S. LaCerda, Kathleen A. Hattler, Brack Dempsey, Edward C. Sadikot, Ruxana T. Shapiro, Shelley Rounds, Sharon I. Goldstein, Ronald H. Pulm Circ Research Articles Treating Veterans with chronic obstructive pulmonary disease complicated by pulmonary hypertension (COPD‐PH) using phosphodiesterase type‐5 inhibitor pharmacotherapy is common, but efficacy data are lacking. To address this further, patients with COPD‐PH from five Department of Veterans Affairs hospitals were randomized (1∶1) to receive placebo or oral tadalafil (40 mg/day) for 12 months. The primary endpoint was changed from baseline in 6‐min walk distance at 12 months. Secondary endpoints included change from baseline in pulmonary vascular resistance, mean pulmonary artery pressure, and symptom burden by the University of California San Diego shortness of breath questionnaire scale at 6 months. A total of 42 subjects (all male; 68 ± 7.6 years old) were randomized to placebo (N = 14) or tadalafil (N = 28). The group imbalance was related to under‐enrollment. Compared to placebo, no significant difference was observed in the tadalafil group for change from the primary endpoint or change in mean pulmonary artery pressure or pulmonary vascular resistance from baseline at 6 months. A clinically meaningful improvement was observed in the secondary endpoint of shortness of breath questionnaire score in the tadalafil versus placebo group at 6 months. There was no significant difference in major adverse events between treatment groups, and tadalafil was well tolerated overall. For Veterans with COPD‐PH enrolled in this study, once‐daily treatment with tadalafil did not improve 6‐min walk distance or cardiopulmonary hemodynamics although a decrease in shortness of breath was observed. Under‐enrollment and imbalanced randomization confound interpreting conclusions from this clinical trial and limit the generalization of our findings. John Wiley and Sons Inc. 2022-03-14 /pmc/articles/PMC9053004/ /pubmed/35506072 http://dx.doi.org/10.1002/pul2.12043 Text en Published 2022. This article is a U.S. Government work and is in the public domain in the USA. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Maron, Bradley A.
Choudhary, Gaurav
Goldstein, Rebekah L.
Garshick, Eric
Jankowich, Matthew
Tucker, Troo J. S.
LaCerda, Kathleen A.
Hattler, Brack
Dempsey, Edward C.
Sadikot, Ruxana T.
Shapiro, Shelley
Rounds, Sharon I.
Goldstein, Ronald H.
Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title_full Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title_fullStr Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title_full_unstemmed Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title_short Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
title_sort tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: a multicenter, placebo‐controlled randomized trial
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053004/
https://www.ncbi.nlm.nih.gov/pubmed/35506072
http://dx.doi.org/10.1002/pul2.12043
work_keys_str_mv AT maronbradleya tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT choudharygaurav tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT goldsteinrebekahl tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT garshickeric tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT jankowichmatthew tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT tuckertroojs tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT lacerdakathleena tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT hattlerbrack tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT dempseyedwardc tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT sadikotruxanat tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT shapiroshelley tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT roundssharoni tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial
AT goldsteinronaldh tadalafilforveteranswithchronicobstructivepulmonarydiseasepulmonaryhypertensionamulticenterplacebocontrolledrandomizedtrial